Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (May 7th Preview)
-
Large pharma M&A reshapes ophthalmology pipelines
Bayer is set to expand its ophthalmology pipeline with its agreement to acquire Perfuse Therapeutics for up to $2.45 billion, the companies said. The deal gives Bayer rights to PER-001, a small-molecule endothelin receptor antagonist delivered via a slow-release, dissolvable intravitreal implant, plus two Phase II programs in glaucoma and diabetic retinopathy. Perfuse previously reported positive Phase IIa results for a single intravitreal PER-001 administration added to standard-of-care IOP-lowering therapies in glaucoma, with responder rates improving versus control at six months. In diabetic retinopathy, Phase IIa data showed improvements in contrast sensitivity and visual acuity measures at week 20 versus worsening in the control arm. Bayer framed the transaction as a complement to its existing ophthalmology footprint, with the acquisition adding mid-stage development programs aimed at conditions that drive leading causes of blindness. The reported structure includes upfront and milestone components, aligning with how large biopharma has been buying differentiated assets to build late-stage-ready franchises. Analysts will likely focus on whether PER-001’s implant-based delivery can translate into durable efficacy and safety across broader patient subgroups, and how quickly Bayer can integrate the program into its development and regulatory plans.
-
Second major deal boosts neurology rare-disease scale in the US
Angelini Pharma agreed to buy Catalyst Pharmaceuticals for roughly $4.1 billion in cash, a move that positions the Italian company to scale its rare-disease footprint and gain a more direct foothold in the U.S. market. The deal values Catalyst at $31.50 per share, representing a 28% premium to the prior 30-day trading period before the transaction became public. Catalyst sells three approved rare-disease medicines and has built additional capabilities in neurology. For Angelini, the acquisition adds U.S. commercialization presence and expands its pipeline with approved products, potentially reducing time-to-impact versus adding only late-stage candidates. The market impact will likely depend on the combined revenue contribution of Catalyst’s current portfolio and Angelini’s ability to maintain growth while integrating a U.S.-focused commercial organization. Investors will also look for updates on how Angelini intends to develop Catalyst’s platform beyond the three approved medicines. No timeline for regulatory review or deal closing was included in the summary provided, but the transaction size suggests it will be closely watched for antitrust and cross-border approvals.
-
A new late-stage execution drive from a comeback MASH player
Madrigal extended its MASH growth strategy through a second licensing deal in the metabolic dysfunction-associated steatohepatitis space. The company licensed Arrowhead’s siRNA asset targeting PNPLA3 (ARO-PNPLA3), valued at up to $1 billion, aiming to add precision genetics to complement its already approved oral therapy, Rezdiffra (resmetirom). The agreement includes a $25 million upfront payment, plus development, regulatory, and sales milestones up to $975 million. Madrigal characterized PNPLA3 as a key genetic driver of MASH in patients carrying the I148M mutation, with Phase 1 data suggesting meaningful liver fat reduction in homozygous carriers following a single dose. Madrigal’s rationale is that an siRNA mechanism could pair with Rezdiffra’s broad effects to cover additional patient subtypes. The company also signaled intent to pursue combination positioning across the MASH population and support a longer runway of differentiated therapies. Investors will likely track whether the PNPLA3 siRNA can demonstrate consistent clinical benefit beyond imaging endpoints and translate genetic stratification into measurable histology or fibrosis improvements.
-
Large oncology diagnostics growth: Tempus accelerates multimodal precision
Tempus reported a 36% year-over-year jump in Q1 revenue to $348.1 million and raised full-year guidance, reinforcing investor focus on its AI-driven diagnostics and data platform. The Chicago-based company said diagnostics revenue climbed 35% to $261.1 million, with oncology volume growth contributing and minimal residual disease (MRD) testing volume rising to about 6,500 tests after a roughly sixfold increase. Management also highlighted platform momentum, including multimodal data and AI model deployment. Tempus noted a multi-year collaboration with Merck to accelerate biomarker discovery and development using its Lens analytical platform, and an expanded collaboration with Gilead to provide enterprise-wide access to Lens and related datasets for oncology pipeline work. While revenue and guidance improved, Tempus also reported higher costs, including increased R&D and SG&A, and a wider net loss for the quarter. The company ended Q1 with $521.2 million in cash and cash equivalents. For the broader sector, the update strengthens the argument that real-world clinical testing volume and algorithmic iteration are converging into a measurable growth engine for precision oncology vendors.
-
Biotech financing: Moonlight AI targets genomic biomarkers from routine imaging
Moonlight AI, a Swiss diagnostic image-analysis startup, raised $3.3 million in private financing as it advances software that identifies genomic biomarkers and disease signatures from routine imaging of blood and cytology smears. The funding was led by Lotus One Investment, VP Venture Partners, and Medin Fund, with N&V Capital and QAI Ventures also participating. The company said it will use the capital to expand its library of whole-slide cytopathology images linked to genomic data with clinical partners, supporting the development and validation of diagnostic programs in myelodysplastic syndrome, non-small cell lung cancer, and chronic lymphocytic leukemia. Moonlight AI’s approach reflects continued investor appetite for image-to-biomarker systems that can leverage existing lab workflows rather than requiring entirely new testing modalities. Scaling the linked dataset and demonstrating reproducible clinical performance will likely be critical next steps. Funding size is modest relative to late-stage players, but it signals early-stage progress in an area where imaging infrastructure and molecular correlation can accelerate translation.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.